Pharmaceutical giant AstraZeneca has acknowledged in court documents, as reported by the British Telegraph, that its COVID-19 vaccine can lead to “rare cases” of blood clots.
Although AstraZeneca is disputing these claims, it has conceded in a legal filing submitted to a British High Court in February that its COVID-19 vaccine “can, in very rare cases, cause” thrombosis with thrombocytopenia syndrome (TTS), which involves blood clots and a low blood platelet count. However, the document also states that “the causal mechanism is not known.”
Moreover, the court document highlights that TTS may occur independently of the AstraZeneca vaccine or any other vaccine. Determining causation in individual cases will require expert evidence.
According to reports, the British High Court has received 51 cases against AstraZeneca thus far. The damages sought, filed on behalf of bereaved relatives, are estimated to exceed $125 million.
